SG11202007961QA - Her2-targeting antigen binding molecules comprising 4-1bbl - Google Patents

Her2-targeting antigen binding molecules comprising 4-1bbl

Info

Publication number: SG11202007961QA
Authority: SG; Singapore
Prior art keywords: 1bbl; her2; antigen binding; binding molecules; targeting antigen
Prior art date: 2018-04-13

Application number

SG11202007961QA

Inventor

Koller Claudia Ferrara

Teemu Junttila

Christian Klein

Pablo Umana

Christina Claus

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-04-13

Filing date

2019-04-12

Publication date

2020-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62002537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202007961Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-04-12 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2020-09-29 Publication of SG11202007961QA publication Critical patent/SG11202007961QA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Cell Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SG11202007961QA 2018-04-13 2019-04-12 Her2-targeting antigen binding molecules comprising 4-1bbl SG11202007961QA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP18167147		2018-04-13
PCT/EP2019/059391 WO2019197600A1 (en)	2018-04-13	2019-04-12	Her2-targeting antigen binding molecules comprising 4-1bbl

Publications (1)

Publication Number	Publication Date
SG11202007961QA true SG11202007961QA (en)	2020-09-29

Family

ID=62002537

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202007961QA SG11202007961QA (en)	2018-04-13	2019-04-12	Her2-targeting antigen binding molecules comprising 4-1bbl

Country Status (20)

Country	Link
US (2)	US12065478B2 (en)
EP (1)	EP3774900A1 (en)
JP (1)	JP7418346B2 (en)
KR (1)	KR20200144114A (en)
CN (1)	CN111741979B (en)
AR (1)	AR114284A1 (en)
AU (1)	AU2019253232A1 (en)
BR (1)	BR112020016997A2 (en)
CA (1)	CA3094235A1 (en)
CL (1)	CL2020002093A1 (en)
CO (1)	CO2020010277A2 (en)
CR (1)	CR20200459A (en)
IL (1)	IL277848A (en)
MA (1)	MA52182A (en)
MX (1)	MX2020010732A (en)
PE (1)	PE20210652A1 (en)
PH (1)	PH12020551689A1 (en)
SG (1)	SG11202007961QA (en)
TW (1)	TWI853809B (en)
WO (1)	WO2019197600A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3489256T3 (en)	2014-11-14	2021-05-25	Hoffmann La Roche	Antigen-binding molecules comprising a TNF family ligand trimer
WO2016156291A1 (en)	2015-03-31	2016-10-06	F. Hoffmann-La Roche Ag	Antigen binding molecules comprising a trimeric tnf family ligand
EP3356403A2 (en)	2015-10-02	2018-08-08	H. Hoffnabb-La Roche Ag	Bispecific antibodies specific for a costimulatory tnf receptor
US10188749B2 (en)	2016-04-14	2019-01-29	Fred Hutchinson Cancer Research Center	Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3559034B1 (en)	2016-12-20	2020-12-02	H. Hoffnabb-La Roche Ag	Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
MA47200A (en)	2017-01-03	2019-11-13	Hoffmann La Roche	BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING A 20H4.9 ANTI-4-1BB CLONE
EP3601345A1 (en)	2017-03-29	2020-02-05	H. Hoffnabb-La Roche Ag	Bispecific antigen binding molecule for a costimulatory tnf receptor
EP3606956B1 (en)	2017-04-04	2024-07-31	F. Hoffmann-La Roche AG	Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
TWI841551B (en)	2018-03-13	2024-05-11	瑞士商赫孚孟拉羅股份公司	Combination therapy with targeted 4-1bb (cd137) agonists
MX2021003548A (en)	2018-10-01	2021-05-27	Hoffmann La Roche	Bispecific antigen binding molecules comprising anti-fap clone 212.
US11608376B2 (en)	2018-12-21	2023-03-21	Hoffmann-La Roche Inc.	Tumor-targeted agonistic CD28 antigen binding molecules
US20230331804A1 (en) *	2019-12-31	2023-10-19	Fred Hutchinson Cancer Center	Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites
CN114929734A (en) *	2020-01-09	2022-08-19	豪夫迈·罗氏有限公司	Novel antigen binding molecules comprising 4-1BBL trimers
AR121706A1 (en)	2020-04-01	2022-06-29	Hoffmann La Roche	OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES
KR20230160366A (en) *	2021-03-23	2023-11-23	피어이스 파마슈티컬즈 게엠베하	HER2/4-1BB bispecific fusion protein for cancer treatment
CN114539420B (en) *	2022-01-20	2024-05-17	荣昌生物制药(烟台)股份有限公司	Anti-B7-H3 monoclonal antibody, anti-B7-H3 xCD 3 bispecific antibody, preparation method and application thereof
US12122813B2 (en) *	2022-02-21	2024-10-22	Ctcells, Inc.	Fusion protein comprising an antigen binding domain and a cytokine trimer domain
JP2025512915A (en) *	2022-04-07	2025-04-22	ユハンコーポレーション	Pharmaceutical composition for treating or preventing cancer with low expression level of HER2
CN120712283A (en) *	2022-12-18	2025-09-26	锐迪恩特生物治疗股份有限公司	Tumor necrosis factor receptor agonist MBS
WO2025191137A1 (en) *	2024-03-15	2025-09-18	Avidicure Ip B.V.	Conjugates of trop2-specific antigen binding proteins and cytokines

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1096187A (en)	1977-04-18	1981-02-24	Souhei Monden	Ornament adapted to be fixed by permanent magnets
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en)	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
WO1990005144A1 (en)	1988-11-11	1990-05-17	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
US6800738B1 (en)	1991-06-14	2004-10-05	Genentech, Inc.	Method for making humanized antibodies
JP4124480B2 (en)	1991-06-14	2008-07-23	ジェネンテック・インコーポレーテッド	Immunoglobulin variants
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
ES2136092T3 (en)	1991-09-23	1999-11-16	Medical Res Council	PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
FI941572L (en)	1991-10-07	1994-05-27	Oncologix Inc	Combination and method of use of anti-erbB-2 monoclonal antibodies
ATE503496T1 (en)	1992-02-06	2011-04-15	Novartis Vaccines & Diagnostic	BIOSYNTHETIC BINDING PROTEIN FOR TUMOR MARKERS
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
CA2225465A1 (en)	1995-08-02	1997-02-13	Newcastle University Ventures Limited	Benzimidazole compounds
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
ES2244066T3 (en)	1997-06-24	2005-12-01	Genentech, Inc.	PROCEDURE AND COMPOSITIONS OF GALACTOSILATED GLICOPROTEINS.
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
DE19742706B4 (en)	1997-09-26	2013-07-25	Pieris Proteolab Ag	lipocalin muteins
WO1999022764A1 (en)	1997-10-31	1999-05-14	Genentech, Inc.	Methods and compositions comprising glycoprotein glycoforms
WO1999029888A1 (en)	1997-12-05	1999-06-17	The Scripps Research Institute	Humanization of murine antibody
AUPP221098A0 (en)	1998-03-06	1998-04-02	Diatech Pty Ltd	V-like domain binding molecules
PT1071700E (en)	1998-04-20	2010-04-23	Glycart Biotechnology Ag	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ES2292682T3 (en)	1998-05-06	2008-03-16	Genentech, Inc.	PURIFICATION OF ANTIBODIES THROUGH IONIC EXCHANGE CHROMATOGRAPHY.
US7115396B2 (en)	1998-12-10	2006-10-03	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
KR100797667B1 (en)	1999-10-04	2008-01-23	메디카고 인코포레이티드	How to regulate transcription of foreign genes
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
CA2421447C (en)	2000-09-08	2012-05-08	Universitat Zurich	Collections of repeat proteins comprising repeat modules
EP1423510A4 (en)	2001-08-03	2005-06-01	Glycart Biotechnology Ag	ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
HUP0600342A3 (en)	2001-10-25	2011-03-28	Genentech Inc	Glycoprotein compositions
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
US7432063B2 (en)	2002-02-14	2008-10-07	Kalobios Pharmaceuticals, Inc.	Methods for affinity maturation
AU2004210088A1 (en) *	2003-02-06	2004-08-19	Micromet Ag	Trimeric polypeptide construct to induce an enduring T cell response
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en)	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
ATE416190T1 (en)	2003-07-04	2008-12-15	Affibody Ab	POLYPEPTIDES WITH BINDING AFFINITY FOR HER2
WO2005019255A1 (en)	2003-08-25	2005-03-03	Pieris Proteolab Ag	Muteins of tear lipocalin
US7288638B2 (en)	2003-10-10	2007-10-30	Bristol-Myers Squibb Company	Fully human antibodies against human 4-1BB
DK2380910T3 (en)	2003-11-05	2015-10-19	Roche Glycart Ag	Antigen binding molecules with increased Fc receptor binding affinity and effector function
JP5006651B2 (en)	2003-12-05	2012-08-22	ブリストル−マイヤーズスクウィブカンパニー	Inhibitor of type 2 vascular endothelial growth factor receptor
MXPA06011199A (en)	2004-03-31	2007-04-16	Genentech Inc	Humanized anti-tgf-beta antibodies.
PL1737891T3 (en)	2004-04-13	2013-08-30	Hoffmann La Roche	Anti-p-selectin antibodies
KR20180091967A (en)	2004-07-22	2018-08-16	제넨테크, 인크.	Her2 antibody composition
TWI380996B (en)	2004-09-17	2013-01-01	Hoffmann La Roche	Anti-ox40l antibodies
NZ553500A (en)	2004-09-23	2009-11-27	Genentech Inc Genentech Inc	Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
JO3000B1 (en)	2004-10-20	2016-09-05	Genentech Inc	Antibody Formulations.
EP1736482A1 (en)	2005-06-20	2006-12-27	INSERM (Institut National de la Santé et de la Recherche Medicale)	Recombinant trimeric 4-1BBL
DE102007001370A1 (en)	2007-01-09	2008-07-10	Curevac Gmbh	RNA-encoded antibodies
EP1958957A1 (en)	2007-02-16	2008-08-20	NascaCell Technologies AG	Polypeptide comprising a knottin protein moiety
SI2235064T1 (en)	2008-01-07	2016-04-29	Amgen Inc.	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
KR101780131B1 (en)	2010-08-13	2017-09-19	로슈 글리카트 아게	Anti-fap antibodies and methods of use
EP2603201B1 (en)	2010-08-13	2020-03-11	Rhode Island Board of Governors for Higher Education	Liposome compositions and methods of use thereof
MY177065A (en)	2010-09-09	2020-09-03	Pfizer	4-1bb binding molecules
KR101614195B1 (en)	2011-03-29	2016-04-20	로슈 글리카트 아게	Antibody fc variants
WO2012143523A1 (en)	2011-04-20	2012-10-26	Genmab A/S	Bispecifc antibodies against her2
CA2947354C (en) *	2012-04-30	2024-03-19	Biocon Limited	Targeted/immunomodulatory fusion proteins and methods for making same
HK1211299A1 (en)	2013-02-26	2016-05-20	罗切格利卡特公司	Bispecific t cell activating antigen binding molecules
EP2961771B1 (en) *	2013-02-26	2020-01-01	Roche Glycart AG	Bispecific t cell activating antigen binding molecules specific to cd3 and cea
JP2016512199A (en) *	2013-03-05	2016-04-25	ベイラーカレッジオブメディスンＢａｙｌｏｒＣｏｌｌｅｇｅＯｆＭｅｄｉｃｉｎｅ	Oncolytic virus
KR20240017102A (en)	2013-12-17	2024-02-06	제넨테크, 인크.	Methods of treating cancers using pd-1 axis binding antagonists and taxanes
EP3192812B1 (en)	2013-12-17	2020-05-27	Genentech, Inc.	Anti-cd3 antibodies and methods of use
KR20160099087A (en) *	2013-12-20	2016-08-19	에프. 호프만-라 로슈 아게	Bispecific her2 antibodies and methods of use
UA117289C2 (en)	2014-04-02	2018-07-10	Ф. Хоффманн-Ля Рош Аг	MULTISPECIFIC ANTIBODY
AU2015292374B2 (en) *	2014-07-25	2020-09-03	Memorial Sloan Kettering Cancer Center	Bispecific HER2 and CD3 binding molecules
CN106660145B (en)	2014-07-31	2018-09-18	株式会社泰珂洛	Cutting tip and bit replacing formula cutting tool
AU2015308527C1 (en)	2014-08-29	2021-07-15	F. Hoffmann-La Roche Ag	Combination therapy of tumor-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
PE20170935A1 (en)	2014-09-12	2017-07-13	Genentech Inc	ANTI-HER2 AND IMMUNOCONJUGATED ANTIBODIES
DK3489256T3 (en)	2014-11-14	2021-05-25	Hoffmann La Roche	Antigen-binding molecules comprising a TNF family ligand trimer
LT3789402T (en)	2014-11-20	2022-09-26	F. Hoffmann-La Roche Ag	Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
DK3029137T3 (en) *	2014-12-06	2019-04-08	Gemoab Monoclonals Gmbh	GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF
WO2016156291A1 (en)	2015-03-31	2016-10-06	F. Hoffmann-La Roche Ag	Antigen binding molecules comprising a trimeric tnf family ligand
MX2017014083A (en) *	2015-05-04	2018-11-09	Pieris Pharmaceuticals Gmbh	Anti-cancer fusion polypeptide.
WO2016207091A1 (en) *	2015-06-24	2016-12-29	F. Hoffmann-La Roche Ag	Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
EP3356403A2 (en)	2015-10-02	2018-08-08	H. Hoffnabb-La Roche Ag	Bispecific antibodies specific for a costimulatory tnf receptor
MY193013A (en)	2015-10-07	2022-09-22	Hoffmann La Roche	Bispecific antibodies with tetravalency for a costimulatory tnf receptor
EP3178848A1 (en) *	2015-12-09	2017-06-14	F. Hoffmann-La Roche AG	Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
EP3231813A1 (en)	2016-03-29	2017-10-18	F. Hoffmann-La Roche AG	Trimeric costimulatory tnf family ligand-containing antigen binding molecules
EP3243836A1 (en)	2016-05-11	2017-11-15	F. Hoffmann-La Roche AG	C-terminally fused tnf family ligand trimer-containing antigen binding molecules
CN109071652B (en)	2016-05-11	2022-09-23	豪夫迈·罗氏有限公司	Antigen binding molecules comprising TNF family ligand trimers and tenascin binding modules
EP3243832A1 (en) *	2016-05-13	2017-11-15	F. Hoffmann-La Roche AG	Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
US10377833B2 (en) *	2016-07-22	2019-08-13	Beijing Mabworks Biotech Co., Ltd.	Bispecific anti-HER2 antibody
PL3519437T3 (en) *	2016-09-30	2022-01-17	F. Hoffmann-La Roche Ag	Bispecific antibodies against p95her2
CN117752798A (en) *	2016-12-19	2024-03-26	豪夫迈·罗氏有限公司	Combination therapy with targeted 4-1BB (CD137) agonists
EP3559034B1 (en)	2016-12-20	2020-12-02	H. Hoffnabb-La Roche Ag	Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
MA47200A (en)	2017-01-03	2019-11-13	Hoffmann La Roche	BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING A 20H4.9 ANTI-4-1BB CLONE
EP3606955B1 (en)	2017-04-05	2024-11-06	F. Hoffmann-La Roche AG	Bispecific antibodies specifically binding to pd1 and lag3
MX2020004573A (en)	2017-11-01	2020-09-25	Hoffmann La Roche	Combination therapy with targeted ox40 agonists.
MA50505A (en)	2017-11-01	2020-09-09	Hoffmann La Roche	2 + 1 BISPECIFIC ANTIBODIES (CONTORSBODIES)
CN111246884A (en)	2017-11-01	2020-06-05	豪夫迈·罗氏有限公司	Novel Antigen Binding Molecules Containing Trimers of TNF Family Ligands
WO2019104716A1 (en) *	2017-12-01	2019-06-06	Adagene Inc.	Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
AU2019236372B2 (en)	2018-03-13	2024-06-20	F. Hoffmann-La Roche Ag	Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies
TWI841551B (en)	2018-03-13	2024-05-11	瑞士商赫孚孟拉羅股份公司	Combination therapy with targeted 4-1bb (cd137) agonists
WO2020007817A1 (en)	2018-07-04	2020-01-09	F. Hoffmann-La Roche Ag	Novel bispecific agonistic 4-1bb antigen binding molecules
US11608376B2 (en)	2018-12-21	2023-03-21	Hoffmann-La Roche Inc.	Tumor-targeted agonistic CD28 antigen binding molecules
CN113677403B (en)	2019-04-12	2024-12-27	豪夫迈·罗氏有限公司	Bispecific antigen-binding molecules comprising lipocalin muteins
JP7678005B2 (en)	2020-06-23	2025-05-15	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Agonistic CD28 antigen-binding molecules targeting Her2

2019
- 2019-04-12 SG SG11202007961QA patent/SG11202007961QA/en unknown
- 2019-04-12 CN CN201980014737.XA patent/CN111741979B/en active Active
- 2019-04-12 TW TW108112817A patent/TWI853809B/en active
- 2019-04-12 CR CR20200459A patent/CR20200459A/en unknown
- 2019-04-12 CA CA3094235A patent/CA3094235A1/en active Pending
- 2019-04-12 KR KR1020207032514A patent/KR20200144114A/en not_active Ceased
- 2019-04-12 BR BR112020016997-8A patent/BR112020016997A2/en unknown
- 2019-04-12 AR ARP190100967A patent/AR114284A1/en not_active Application Discontinuation
- 2019-04-12 AU AU2019253232A patent/AU2019253232A1/en not_active Abandoned
- 2019-04-12 PE PE2020001136A patent/PE20210652A1/en unknown
- 2019-04-12 EP EP19716184.7A patent/EP3774900A1/en active Pending
- 2019-04-12 MX MX2020010732A patent/MX2020010732A/en unknown
- 2019-04-12 WO PCT/EP2019/059391 patent/WO2019197600A1/en not_active Ceased
- 2019-04-12 MA MA052182A patent/MA52182A/en unknown
- 2019-04-12 JP JP2020555351A patent/JP7418346B2/en active Active
2020
- 2020-08-13 CL CL2020002093A patent/CL2020002093A1/en unknown
- 2020-08-20 CO CONC2020/0010277A patent/CO2020010277A2/en unknown
- 2020-10-07 IL IL277848A patent/IL277848A/en unknown
- 2020-10-09 US US17/066,711 patent/US12065478B2/en active Active
- 2020-10-13 PH PH12020551689A patent/PH12020551689A1/en unknown
2024
- 2024-07-26 US US18/786,187 patent/US20250066448A1/en active Pending

Also Published As

Publication number	Publication date
CL2020002093A1 (en)	2020-12-28
JP7418346B2 (en)	2024-01-19
AU2019253232A1 (en)	2020-09-03
MX2020010732A (en)	2020-11-09
WO2019197600A1 (en)	2019-10-17
US20250066448A1 (en)	2025-02-27
JP2021520805A (en)	2021-08-26
CO2020010277A2 (en)	2020-08-31
CN111741979A (en)	2020-10-02
PH12020551689A1 (en)	2021-07-19
CR20200459A (en)	2020-11-11
CN111741979B (en)	2024-07-02
AR114284A1 (en)	2020-08-12
CA3094235A1 (en)	2019-10-17
BR112020016997A2 (en)	2021-01-19
US20210024610A1 (en)	2021-01-28
TW202012440A (en)	2020-04-01
TWI853809B (en)	2024-09-01
PE20210652A1 (en)	2021-03-26
MA52182A (en)	2021-02-17
KR20200144114A (en)	2020-12-28
US12065478B2 (en)	2024-08-20
EP3774900A1 (en)	2021-02-17
IL277848A (en)	2020-11-30

Publication	Publication Date	Title
IL277848A (en)	2020-11-30	Her2-targeting antigen binding molecules comprising 4-1bbl
IL275510A (en)	2020-08-31	Ror1-specific antigen binding molecules
IL281901A (en)	2021-05-31	Multivalent igm- and iga-fc-based binding molecules
IL273886B (en)	2021-10-31	B cell maturation antigen binding proteins
IL263083A (en)	2018-12-31	Single chain variable fragment cd3 binding proteins
DK3645570T3 (en)	2021-04-26	VISTA antigen binding molecules
GB201811403D0 (en)	2018-08-29	Antibody molecules
GB201811410D0 (en)	2018-08-29	OX40 Binding molecules
GB201811408D0 (en)	2018-08-29	CD137 Binding Molecules
GB201901305D0 (en)	2019-03-20	Specific binding molecules
GB201702091D0 (en)	2017-03-22	Specific binding molecules
IL287555A (en)	2021-12-01	Binding molecules
GB201802338D0 (en)	2018-03-28	Antigen binding proteins
GB201915282D0 (en)	2019-12-04	Specific binding molecules
SG11202109535SA (en)	2021-10-28	Cd3 binding molecules
IL288561A (en)	2022-02-01	Anti-gal9 immune-inhibiting binding molecules
IL269752B (en)	2020-03-31	Fgfr3 binding molecules
ZA201906821B (en)	2021-06-30	Anti-jagged1 antigen binding proteins
GB201820446D0 (en)	2019-01-30	Antigen binding molecules that bind light
SG11202113222PA (en)	2021-12-30	Activating anti-gal9 binding molecules
GB201906118D0 (en)	2019-06-12	Anti-LAG-3 binding molecules
GB201904328D0 (en)	2019-05-15	Specific binding molecules
GB201614627D0 (en)	2016-10-12	Antigen binding proteins
GB201914468D0 (en)	2019-11-20	Binding Molecules
GB201912030D0 (en)	2019-10-02	Binding molecules